Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted;Disponibilité et accessibilité financière des nouveaux médicaments dans les pays d’Amérique latine où ont été menés des essais cliniques pivots;La disponibilidad y asequibilidad de nuevos medicamentos en los países de América Latina en los que se llevaron a cabo ensayos clínicos decisivos

Bulletin of the World Health Organization

Volumn 93, Issue 10, 2015, Pages 674-683

  Homedes, Núria ^a   Ugalde, Antonio ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCIALIZATION; DRUG; ETHICS; FEDERAL SYSTEM; HEALTH CARE; MEDICAL GEOGRAPHY; MEDICINE; PHARMACEUTICAL INDUSTRY; PRICE DYNAMICS; RESEARCH WORK; RESOURCE AVAILABILITY; SAFETY; WAGE;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LATIN AMERICAN MEDICINE; PRACTICE GUIDELINE; WORLD HEALTH ORGANIZATION;

LATIN AMERICA;

EID: 84943166318     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.14.151290     Document Type: Article

References (38)

1. The 2014 drug trend report. St. Louis: The express scripts holding company; 2015. Available from: http://lab.express-scripts.com/drug-trend-report [cited 2015 May 11].
2. 2011 novel new drugs. Silver Spring: Center for Drug Evaluation and Research, US Food and Drug Administration; 2012. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM293663.pdf [cited 2015 May 11].
3. New molecular entity approvals for 2012 [Internet]. Silver Spring: US Food and Drug Administration; 2015. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm336115.htm [cited 2015 May 11].
4. Drugs@FDA [Internet]. Silver Spring: US Food and Drug Administration; 2015. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [cited 2015 May 15].
5. Vademecum Nacional de Medicamentos [Internet]. Buenos Aires, ANMAT, 2014. Available from: http://anmatvademecum.servicios.pami.org.ar/index.html [cited 2015 May 27]. Spanish.
6. Listado Oficial de Medicamentos Comercializados [Internet]. Buenos Aires, ANMAT, 2014. Available from: http://anmatvademecum.servicios.pami.org.ar/index.html [cited 2015 May 27]. Spanish.
7. Listas de Preços de Medicamentos [Internet]. Brasília: Agência Nacional de Vigilância Sanitária; 2015. Available from: http://tinyurl.com/nwe9go4 [cited 2015 May 15]. Portuguese.
8. Medicamentos Analisados [Internet]. Brasília: Agência Nacional de Vigilância Sanitária; 2015. Available from: http://www.anvisa.gov.br/datavisa/fila_medicamento/index.asp [cited 2015 May 15]. Portuguese.
9. Consulta Datos de Productos [Internet]. Bogota (Colombia): INVIMA; 2014. Available from: http://web.sivicos.gov.co:8080/consultas/consultas/consreg_encabcum.jsp [cited 2015 May 15]. Spanish.
10. Listado de entidades químicas con información no divulgada protegida según el Decreto 2085 de 2002 corte a 31 de Julio de 2014 [Internet]. Bogota (Colombia): INVIMA; 2014. Available from: https://www.invima.gov.co/images/pdf/tramites-y-servicios/moleculas-protegidas/Listado%20de%20entidades%20quimicas%20protegidas%20a%2031%20de%20Julio.pdf [cited 2015 May 15]. Spanish.
11. Precios de Medicamentos-Circular 2 de 2012 Excel [Internet]. Bogotá: Ministerio de Salud y Protección Social; 2013. Available from: http://www.sispro.gov.co/recursosapp/app/Pages/Precios%20de%20Medicamentos%20-%20Circular%202%20de%202012%20Excel.aspx [cited 2015 Mar 15]. Spanish.
12. Sistema de consulta de productos registrados [Internet]. Santiago: Instituto de Salud Pública de Chile; 2015. Available from: http://registrosanitario.ispch.gob.cl/ [cited 2015 May 15]. Spanish.
13. Precios de Remedios-Chile [Internet]. Available from: http://www.preciosderemedios.cl/ [cited 2014 August 18]. Spanish.
14. Precios registrados de medicamentos con patente vigente. Mexico DF: Ministerio de Economia; 2014. Available from: http://www.economia.gob.mx/files/transparencia/focalizada/lista_precios_maximos_medicamentos_de_patente_2014_0829.xls [cited 2015 May 25].
15. Precios de Remedios-Mexico [Internet]. Available from: http://www.preciosderemedios.mx [cited 2014 September 8]. Spanish.
16. Catálogo de Productos Farmacéuticos. Lima: Ministerio de Salud Peru; 2015. Available from: http://observatorio.digemid.minsa.gob.pe/Precios/ProcesoL/Catalogo/CatalogoProductos.aspx?over=1 [cited 2015 May 25]. Spanish.
17. Módulo de Consulta de Precios. Lima: Ministerio de Salud Peru; 2015. Available from: http://observatorio.digemid.minsa.gob.pe [cited 2015 May 25]. Spanish.
18. PAHO. Health systems and social protection in health. Washington: Pan American Health Organization; 2012.
19. Niëns LM, Brouwer WBF. Measuring the affordability of medicines: importance and challenges. Health Policy. 2013 Sep;112(1-2):45-52. doi: http://dx.doi.org/10.1016/j.healthpol.2013.05.018 PMID: 23827263
20. Niëns LM, Van de Poel E, Cameron A, Ewen M, Laing R, Brouwer WB. Practical measurement of affordability: an application to medicines. Bull World Health Organ. 2012 Mar 1;90(3):219-27. doi: http://dx.doi.org/10.2471/BLT.10.084087 PMID: 22461717
21. O'Donnell O, van Doorslaer E, Wagstaff A, Lindelow M. Analyzing health equity using household survey data: a guide to techniques and their implementation. Washington: World Bank; 2008. Available from: http://siteresources.worldbank.org/INTPAH/Resources/Publications/459843-1195594469249/HealthEquityFINAL.pdf [cited 2015 May 11].
22. Trade, foreign policy, diplomacy and health: access to medicines. Geneva: World Health Organization; 2015. Available from: http://www.who.int/trade/glossary/story002/en/ [cited 2015 May 12].
23. Homedes N, Ugalde A. Globalization and clinical research in Latin America. In: Homedes N, Ugalde A, editors. Clinical trials in Latin America: where ethics and business clash. Dordrecht: Springer; 2014. pp. 55-78. doi: http://dx.doi.org/10.1007/978-3-319-01363-3_3
24. Council for International Organizations of Medical Sciences, World Health Organization. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS, 2002. Available from: http://www.cioms.ch/publications/layout_guide2002.pdf [cited 2015 May 25].
25. Universal Declaration on Bioethics and Human Rights. Paris: UNESCO General Assembly. October 19, 2005. Available from: http://www.unesco.org/new/en/social-and-human-sciences/themes/bioethics/bioethics-and-human-rights/ [cited 2015 Sept 1].
26. World Medical Association. Declaration of Helsinki. Fortaleza, Brasil. 64th WMA General Assembly. October 2013. Available from: http://www.wma.net/en/30publications/10policies/b3/ [cited 2015 Sept 1].
27. International ethical guidelines for biomedical research involving human subjects. Geneva: Council for International Organizations of Medical Sciences; 2002. Available from: http://www.cioms.ch/publications/layout_guide2002.pdf [cited 2015 May 12].
28. ICDRA. Es el momento de actuar: aseguren el acceso a productos bio-terapéuticos asequibles. Declaración de la Sociedad Civil para pre-ICDRA e ICDRA. Boletín Fármacos. 2014;17(4):81-2. Spanish.
29. Calderón JM. Carta abierta al Señor Presidente de la República de Colombia. Boletín Fármacos. 2014;17(4):91-2. Spanish.
30. Budget-busters: the shift to high-priced innovator drugs in the USA. Boston: EvaluatePharma; 2014. Available from: http://info.evaluategroup.com/rs/evaluatepharmaltd/images/SV2014.pdf [cited 2015 May 12].
31. Light DW, Warburton R. Demythologizing the high costs of pharmaceutical research. Biosocieties. 2011;6(1):34-50. doi: http://dx.doi.org/10.1057/biosoc.2010.40
32. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013 May 30;121(22):4439-42. doi: http://dx.doi.org/10.1182/blood-2013-03-490003 PMID: 23620577
33. Ward A, Neville S. Drug cost watchdog chief calls for honesty with public. Financial Times, August 22, 2014. Available from: http://www.ft.com/cms/s/0/c62145a6-2896-11e4-8bda-00144feabdc0.html#axzz3UwNC6Xov [cited 2015 Sept 1].
34. Werth B. A tale of two drugs. MIT Technology review. 2013 Oct 22. Available from: http://www.technologyreview.com/featuredstory/520441/a-tale-of-two-drugs/ [cited 2015 May 12].
35. Steenhuysen J. FDA cancer chief says 'escalating' drug prices can't continue. Reuters. 2014 Jun 1. Available from: http://www.reuters.com/article/2014/06/01/us-health-cancer-fda-idUSKBN0EC13W20140601 [cited 2015 May 12].
36. Consensus framework for ethical collaboration between patients' organisations, healthcare professionals and the pharmaceutical industry. London: International Alliance of Patients' Organizations, International Council of Nurses, IFPMA, International Pharmaceutical Federation, World Medical Association; 2014. Available from: http://www.wma.net/en/20activities/60campaigns/13consensus/Consensus_Framework-vF.pdf [cited 2015 May 12].
37. Universal Declaration on Bioethics and Human Rights. Paris: United Nations Educational, Scientific and Cultural Organization; 2005.
38. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191-4. doi: http://dx.doi.org/10.1001/jama.2013.281053 PMID: 24141714